Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Unfractionated Heparin Clear all
Completed Phase 2 Interventional

Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients

NCT00001311
View directory record Official record
Conditions
Cataracts
Interventions
heparin-surface modified intraocular lens
Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 8:05 PM EDT
Terminated Phase 1 Interventional Results available

Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

NCT04994977
View directory record Official record
Conditions
Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma
Interventions
Melphalan, Carboplatin, Topotecan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
0 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 17, 2026, 8:05 PM EDT
Withdrawn Not applicable Interventional

Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates

NCT00879957
View directory record Official record
Conditions
Infant, Premature, Anticoagulants, Thrombosis
Interventions
heparin, No heparin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 17, 2026, 8:05 PM EDT
Active, not recruiting Phase 4 Interventional

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulation with heparin, EkoSonicTM Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 17, 2026, 8:05 PM EDT
Active, not recruiting Not applicable Interventional

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

NCT03537586
View directory record Official record
Conditions
Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia
Interventions
Bivalirudin, Adenosine, Heparin, Pressure-Temperature Sensor Guidewire, Guiding Catheter
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19

NCT04367831
View directory record Official record
Conditions
COVID-19, Venous Thromboses, Arterial Thrombosis
Interventions
Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC, Enoxaparin/Lovenox Intermediate Dose
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Not applicable Interventional

The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke

NCT03805308
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Intra-arterial Therapy
Procedure
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Pomona, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

Enoxaparin Dosing in Obesity

NCT01798550
View directory record Official record
Conditions
Obesity
Interventions
Enoxaparin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

NCT00721760
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin sodium, Semuloparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Not applicable Interventional

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03867461
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous Sinus Stenting, Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range), Adjustment to Mean Arterial Pressure (100-110 mmHg range), Adjustment to Mean Arterial Pressure (60-80 mmHg range), Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Not applicable Interventional Results available

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
Drug · Behavioral · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding "Heparin Resistance" in Cardiac Surgery

NCT01598883
View directory record Official record
Conditions
Cardiopulmonary Bypass, Altered Heparin Response
Interventions
Heparin, ATryn
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

NCT02925923
View directory record Official record
Conditions
Acute Coronary Syndrome, Angina, Unstable
Interventions
Ticagrelor, Eptifibatide, Clopidogrel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 17, 2026, 8:05 PM EDT
Suspended Phase 1 Interventional

Islet Allotransplantation in Type 1 Diabetes

NCT01705899
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Pancreatic Islets
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 17, 2026, 8:05 PM EDT
Withdrawn Not applicable Interventional

Anticoagulation in Blunt Cerebrovascular Injuries

NCT00494156
View directory record Official record
Conditions
Carotid Artery Injury, Vertebral Artery Injury
Interventions
heparin, aspirin and clopidogrel
Drug
Lead sponsor
C. Clay Cothren, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 17, 2026, 8:05 PM EDT
Completed No phase listed Observational

Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2

NCT02526485
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Blood Draw
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 17, 2026, 8:05 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 8:05 PM EDT
Completed No phase listed Observational

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

NCT04141228
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
28,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Flemington, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

NCT02557672
View directory record Official record
Conditions
Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions
Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP)
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

NCT00133731
View directory record Official record
Conditions
Angioplasty, Transluminal, Percutaneous Coronary
Interventions
Otamixaban (XRP0673), Unfractionated Heparin, Percutaneous Coronary Intervention
Drug · Procedure
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
37
States / cities
Los Angeles, California • Santa Ana, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 17, 2026, 8:05 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116
View directory record Official record
Conditions
Acquired Antithrombin Deficiency
Interventions
Human plasma derived antithrombin, Placebo
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 8:05 PM EDT